SI

SillaJen, Inc.

Biotechnology company developing oncolytic viral therapies for cancer treatment.

215600 | KO

Overview

Corporate Details

ISIN(s):
KR7215600008
LEI:
Country:
South Korea
Address:
서울특별시 중구 청계천로 106 3층(수표동, 크리스탈스퀘어), 중구

Description

SillaJen, Inc. is a biotechnology company focused on the research and development of oncolytic immunotherapeutics for cancer treatment. The company engineers genetically modified viruses designed to selectively target and destroy cancer cells while stimulating a systemic anti-tumor immune response. Its lead product candidate is Pexa-Vec (JX-594), an oncolytic vaccinia virus developed for the treatment of various solid tumors. SillaJen's core activity involves advancing its pipeline of novel cancer-fighting viral therapies through clinical development.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-05-29 00:00
[기재정정]주식매수선택권부여에관한신고
Korean 23.1 KB
2025-05-27 00:00
[기재정정]주요사항보고서(회사합병결정)
Korean 85.3 KB
2025-05-22 00:00
[기재정정]분기보고서 (2025.03)
Korean 1.2 MB
2025-05-15 00:00
[기재정정]사업보고서 (2024.12)
Korean 1.9 MB
2025-05-15 00:00
분기보고서 (2025.03)
Korean 1.2 MB
2025-04-24 00:00
주요사항보고서(회사합병결정)
Korean 75.9 KB
2025-04-24 00:00
주주명부폐쇄기간또는기준일설정
Korean 4.5 KB
2025-04-22 00:00
[기재정정]투자판단관련주요경영사항 (유사분열 체크포인트 억제제(MCI) 후보물질의 기술 도입 계약 체결)
Korean 16.2 KB
2025-04-21 00:00
투자판단관련주요경영사항(임상시험계획변경승인) (진행성 고형암 또는 재발성/불응성 급성 골수성 백혈병 환자를 대상으로 B…
Korean 23.4 KB
2025-04-21 00:00
[기재정정]투자판단관련주요경영사항 (유사분열 체크포인트 억제제(MCI) 후보물질의 기술 도입 계약 체결)
Korean 18.6 KB
2025-04-21 00:00
투자판단관련주요경영사항 (유사분열 체크포인트 억제제(MCI) BAL0891의 PH1128(물질특허)와 P1129(바이오…
Korean 9.5 KB
2025-04-17 00:00
[기재정정]주요사항보고서(유상증자결정)
Korean 39.0 KB
2025-04-14 00:00
본점소재지변경
Korean 5.1 KB
2025-04-03 00:00
증권발행결과(자율공시) (제3자배정 유상증자)
Korean 5.6 KB
2025-04-01 00:00
증권발행결과(자율공시) (제34회차 CB)
Korean 5.6 KB

Automate Your Workflow. Get a real-time feed of all SillaJen, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for SillaJen, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for SillaJen, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

1NKEMIA Logo
Biotechnology company providing R&D and services for the life sciences sector.
Spain
IKM
2cureX AB Logo
Develops an IVD test using 3D tumoroids to predict patient response to cancer drugs.
Sweden
2CUREX
Abera Bioscience AB Logo
Develops mucosal vaccines using a proprietary Outer Membrane Vesicle (OMV) platform.
Sweden
ABERA
Clinical-stage biopharma developing therapeutics for oncology and viral diseases.
South Korea
203400
ABL Bio Inc. Logo
Develops bispecific antibody therapeutics for oncology and neurodegenerative diseases.
South Korea
298380
Abpro Holdings, Inc. Logo
Clinical-stage biotech developing antibody therapeutics for oncology and ophthalmology.
United States of America
ABP
Absci Corp Logo
A generative AI drug creation company developing biologic medicines.
United States of America
ABSI
Achiko AG Logo
A digital services platform for cross-border business compliance and engagement.
Switzerland
ACHI
Active Biotech Logo
Biotechnology company developing drugs for oncology and inflammatory eye disorders.
Sweden
ACTI
Adagene Inc. Logo
Clinical-stage biotech developing antibody-based immunotherapies for oncology.
United States of America
ADAG

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.